Why Invest in Sysmex

Our Earnings Power

Playing an active role in the growing healthcare sector

The growth of the healthcare domain is expected to continue, driven by factors such as the growing global population, expanding healthcare demands, and technological innovation. The healthcare infrastructure in emerging countries continues to develop, while developed countries are seeing expanding needs for advanced diagnostics and preventive healthcare.
Under these circumstances, in vitro diagnostics are becoming even more essential to health checkups and disease diagnosis, as well as determining treatment policies.
Sysmex’s core business is centered on in vitro diagnostics using blood and urine. We hold the largest share in the global hematology market, and have contributed to widespread adoption of testing and improvements to healthcare quality through collaboration with medical institutions and public authorities. These business activities are expected to remain a stable source of growth as we continue to play a significant role in supporting people’s health as a leader in the in vitro diagnostics market.

Stable Revenue Model

Sysmex’s main revenue sources are instruments, reagents, and service & support through customer care. In addition to reliable testing results achieved through both instruments and reagents, we enhance customer satisfaction through high-quality service & support, creating a cycle that drives further product adoption. It is this cycle that underpins our sustained growth and continued revenue generation.

A diagram illustrating a virtuous cycle: instruments are sold, and reagents along with service & support are continuously provided. This ongoing support leads to high customer satisfaction, which creates a virtuous circle that ultimately drives further instrument sales. A diagram illustrating a virtuous cycle: instruments are sold, and reagents along with service & support are continuously provided. This ongoing support leads to high customer satisfaction, which creates a virtuous circle that ultimately drives further instrument sales.

Reagents are essential for conducting tests, and service & support are integral to accurate testing results. What sets us apart is that even after installing instruments, we continue to generate revenue through reagents and service & support. Reagents have higher profitability than instruments, and their sales grow in proportion to the number of installed instruments and tests conducted. Accordingly, by expanding our market share among large-scale facilities, which consume higher volumes of reagents, and by broadening our assay menu to include testing parameters of high clinical significance, we increase the revenue share of reagents while also increasing the proportion of service & support revenue.
As a result, revenue growth from reagents and service & support has been significant, and the share of these stable revenue sources has been increasing year by year.

A graph and a pie chart illustrating a business model in which reagents and service & support account for more than 70% of revenue, enabling stable earnings through recurring revenue. A graph and a pie chart illustrating a business model in which reagents and service & support account for more than 70% of revenue, enabling stable earnings through recurring revenue.

Please also refer to our other two core capabilities.

2. Ability To Create
3. Ability To Deliver And Support